Illumina plans to launch a whole-genome sequencing measurable residual disease (MRD) detection kit in 2027. The research-use-only kit is intended to help more laboratories adopt MRD testing for clinical research and is positioned as Illumina’s first product in a new oncology portfolio. MRD assays are used to detect low levels of remaining disease after therapy and can help guide response monitoring and treatment decisions, but widespread adoption depends on accessible workflows and validated platforms. Illumina’s approach—whole-genome sequencing—signals an emphasis on broad assay coverage rather than single-gene or targeted readouts. For diagnostics operators and oncology trial teams, the kit could reduce onboarding friction for MRD measurements in studies, particularly where researchers need consistent, high-throughput genomic data. Industry-watch item: whether the product’s sequencing depth and bioinformatics workflow will translate into performance suitable for multi-study comparability.